Probmet Therapeutics develops a peptide mimetic targeting the ADAM22 receptor to create precision therapies for breast cancer patients with brain metastases. This approach addresses the lack of effective treatments for metastatic tumors, particularly those that can cross the blood-brain barrier, improving patient outcomes and survival rates.
Funding
$560K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Breast cancer patients often develop brain metastases, which are difficult to treat due to the blood-brain barrier and the limited effectiveness of existing therapies. Current treatments primarily target the primary tumor and may not be effective against metastatic tumors that have developed resistance.
Solution
Probmet Therapeutics is developing a peptide mimetic that targets the ADAM22 receptor, a cancer-specific target highly expressed in both primary and metastatic breast tumors. This targeted therapeutic approach aims to provide precision oncology for breast cancer patients with brain metastases. The peptide is designed to cross the blood-brain barrier, enabling effective treatment of tumors in the central nervous system. By targeting ADAM22, Probmet Therapeutics seeks to reduce tumor cell growth and improve outcomes for patients with limited treatment options.
Target Audience
The primary target audience is breast cancer patients with brain metastases, as well as oncologists and medical professionals seeking more effective treatment options for this patient population.
Features
- Peptide mimetic drug targeting the ADAM22 receptor
- ADAM22 target validated in human and animal models of breast cancer
- Demonstrated efficacy in reducing tumor cell growth
- Ability to cross the blood-brain barrier for effective treatment of brain metastases
- Designed as a targeted therapeutic and biomarker selection strategy